Dr Connor Blair is Co-Founder and Chief Scientific Officer of Disruptyx Therapeutics Ltd (DRx), a Glasgow-based biotech company focused on the discovery and development of precision therapeutics against treatment resistant cancers. Prior to the incorporation of DRx, Dr Blair carried out his industry-led PhD and Post-Doctoral Research at the University of Glasgow, specialising in translational and molecular pharmacology.
Connor’s drug discovery research encompassed projects across a broad-spectrum of disease indications including cancer, cardiovascular disease, neurodegenerative disease, autoimmune disease, and infectious disease (specifically COVID-19). During this time Dr Blair served as Principal Scientist at Portage Glasgow Ltd (a subsidiary of Portage Biotech Inc.) where he was awarded Innovator of the Future at the Scottish Knowledge Exchange Awards (Interface UK) for his research. Connor’s expertise lies predominantly within drug discovery and development, where his research remains dedicated to translating the next-generation of precision therapeutics to patients with urgent unmet clinical needs.
Dr Connor Blair joined the SSAC on 1 December 2022.
